Innovation Pharmaceuticals Inc (IPIX)

[Justfactsmam]

I would concur with your statements with one qualification:

"... pre-review (of Peer Review Articles") should be made available in Sept and that is all we need to advance the Brilacidin program at the current time."

It is actually "reporting" to the company of the DATA from RBL's complete testing on Covid-19 which is important to move forward...not the written pre-review of the Peer Review Article...therefore as soon as the data is released the (any day now on latest testing results) ... those results along with the prior results from both the RBL and PHRI would be available to inform and confirm to Human Trial sites and the FDA...(the nature of mechanisms of Brilacidin's interaction with Covid-19 and results in the labs)... which all information needed when IPIX submits application to the FDA for IND/EUA.

IMO...the next reporting by RBL (GMU) will spur on surge of activity ...the final domino result being Human Trials who's results should be reported rather quickly...maybe even spurring on immediate Compassionate Use Approval.

"The pre-review(s)IMO should be what knocks the socks off of Brilacidin being relegated to the "quiet" corner. It should start hellacious articles from all forms of media - written articles, radio, TV and even governmental mentioning IMO."

The actual Peer Review Articles...as you indicated should "knock the socks" off the medical community about Brilacidin...since IMO they will clearly inform them of the dynamic effect Brilacidin will be shown to have on Covid-19...as (IMO) an relatively inexpensive standalone Therapeutic to destroy Covid-19.